

**BIOCON GROUP**

**FACT SHEET**

**December - 2021**

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
<b>Particulars</b>	<b>Q3'FY 22</b>	<b>Q3'FY 21</b>	<b>Variance %</b>
<b><u>INCOME</u></b>			
Generics	607	567	7%
Biosimilars	981	769	28%
Novel Biologics	16	-	100%
Research services	641	585	10%
Inter-segment	(72)	(63)	13%
<b>Revenue from operations #</b>	<b>2,174</b>	<b>1,857</b>	<b>17%</b>
Other income	48	28	73%
<b>TOTAL REVENUE</b>	<b>2,223</b>	<b>1,885</b>	<b>18%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	798	638	25%
Staff costs	450	411	10%
Research & Development expenses*	138	171	-19%
Other expenses	300	239	26%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,686</b>	<b>1,458</b>	<b>16%</b>
<b>EBITDA</b>	<b>537</b>	<b>428</b>	<b>25%</b>
Interest & Finance charges	15	5	206%
Depreciation & Amortisation	206	186	10%
Share of loss / (profit) in JV / Associate, net	47	1	100%
<b>PBT</b>	<b>269</b>	<b>236</b>	<b>14%</b>
Taxes	49	49	1%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>220</b>	<b>187</b>	<b>18%</b>
Minority interest	33	18	81%
<b>NET PROFIT FOR THE PERIOD</b>	<b>187</b>	<b>169</b>	<b>11%</b>
<b>EPS Rs.</b>	<b>1.6</b>	<b>1.4</b>	
<i># Licensing Income</i>	17	11	52%
<i>* Gross Research &amp; Development expenses</i>	178	183	-3%

<b>BIOCON LIMITED (CONSOLIDATED)</b>			(Rs. Crores)
<b>PROFIT &amp; LOSS STATEMENT</b>			
Particulars	Q3' FY 22	Q2' FY 22	Variance %
<b>INCOME</b>			
Generics	607	530	15%
Biosimilars	981	743	32%
Novel Biologics	16	12	-
Research services	641	610	5%
Inter-segment	(72)	(54)	32%
<b>Revenue from operations #</b>	<b>2,174</b>	<b>1,840</b>	<b>18%</b>
Other income	48	105	-54%
<b>TOTAL REVENUE</b>	<b>2,223</b>	<b>1,945</b>	<b>14%</b>
<b>EXPENDITURE</b>			
Material & Power costs	798	641	24%
Staff costs	450	437	3%
Research & Development expenses*	138	146	-6%
Other expenses	300	170	76%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,686</b>	<b>1,395</b>	<b>21%</b>
<b>EBITDA</b>	<b>537</b>	<b>551</b>	<b>-3%</b>
Interest & Finance charges	15	23	-35%
Depreciation & Amortisation	206	202	2%
Share of loss / (profit) in JV / Associate, net	47	51	100%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>269</b>	<b>276</b>	<b>-3%</b>
Exceptional item, Net	-	(70)	-100%
<b>PBT</b>	<b>269</b>	<b>206</b>	<b>31%</b>
Taxes	49	59	-16%
Taxes on exceptional item	-	(12)	-100%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>220</b>	<b>160</b>	<b>38%</b>
Minority interest	33	29	11%
Minority interest on exceptional item	-	(8)	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>187</b>	<b>138</b>	<b>35%</b>
<b>EPS Rs.</b>	<b>1.6</b>	<b>1.2</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>			
	187	188	-1%
Exceptional item, net of taxes	-	(50)	
<b>NET PROFIT FOR THE PERIOD</b>	<b>187</b>	<b>138</b>	<b>35%</b>
<i># Licensing Income</i>	17	13	
<i>* Gross Research &amp; Development expenses</i>	178	165	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	9M' FY 22	9M' FY 21	Variance %
<b>INCOME</b>			
Generics	1,624	1,792	-9%
Biosimilars	2,482	2,137	16%
Novel Biologics	39	-	100
Research services	1,846	1,526	21%
Inter-segment	(215)	(154)	40%
<b>Revenue from operations #</b>	<b>5,775</b>	<b>5,301</b>	<b>9%</b>
Other income	145	62	136%
<b>TOTAL REVENUE</b>	<b>5,921</b>	<b>5,363</b>	<b>10%</b>
<b>EXPENDITURE</b>			
Material & Power costs	2,124	1,867	14%
Staff costs	1,282	1,152	11%
Research & Development expenses*	404	426	-5%
Other expenses	587	652	-10%
<b>Manufacturing, staff &amp; other expenses</b>	<b>4,397</b>	<b>4,097</b>	<b>7%</b>
<b>EBITDA</b>	<b>1,524</b>	<b>1,266</b>	<b>20%</b>
Interest & Finance charges	57	24	140%
Depreciation & Amortisation	602	531	13%
Share of loss / (profit) in JV / Associate, net	154	10	100%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>711</b>	<b>702</b>	<b>1%</b>
Exceptional item, Net	(70)	-	-
<b>PBT</b>	<b>641</b>	<b>702</b>	<b>-9%</b>
Taxes	165	152	9%
Taxes on exceptional item	(12)	-	0%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>488</b>	<b>550</b>	<b>-11%</b>
Minority interest	86	63	37%
Minority interest on exceptional item	(8)	-	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>410</b>	<b>487</b>	<b>-16%</b>
<b>EPS Rs.</b>	<b>3.4</b>	<b>4.1</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>			
	460	487	-6%
Exceptional item, net of taxes	(50)	-	100%
<b>NET PROFIT FOR THE PERIOD</b>	<b>410</b>	<b>487</b>	<b>-16%</b>
# Licensing Income	40	32	
* Gross Research & Development expenses	479	491	

**BIOCON LIMITED (CONSOLIDATED)**  
**BALANCE SHEET**

(Rs Crores)

Particulars	December 31, 2021	March 31, 2021
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	5,633	5,557
(b) Capital work-in-progress	3,093	2,254
(c) Right-of-use assets	147	153
(d) Goodwill	26	26
(e) Other intangible assets	610	627
(f) Intangible assets under development	637	547
(g) Investment in associates and a joint venture	30	180
(h) Financial assets		
Investments	217	564
Derivative assets	116	66
Other financial assets	89	201
(i) Income tax asset, net	343	265
(j) Deferred tax asset, net	287	308
(k) Other non-current assets	152	176
<b>Non-current assets</b>	<b>11,380</b>	<b>10,922</b>
<b>Current assets</b>		
(a) Inventories	2,393	1,867
(b) Financial assets		
Investments	1,346	1,209
Trade receivables	1,345	1,218
Cash and cash equivalents	729	953
Other bank balances	992	1,062
Derivative assets	112	83
Loans and advances	67	-
Other financial assets	800	793
(c) Other current assets	330	364
(c) Assets held for sale	-	52
<b>Current assets</b>	<b>8,113</b>	<b>7,600</b>
<b>TOTAL - ASSETS</b>	<b>19,493</b>	<b>18,522</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	600	600
(b) Other equity	7,514	7,027
<b>Equity attributable to owners of the Company</b>	<b>8,114</b>	<b>7,627</b>
Non-controlling interests	980	881
<b>Total Equity</b>	<b>9,094</b>	<b>8,508</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	3,112	2,962
Lease liabilities	101	114
Derivative liabilities	27	62
Other financial liabilities	1,503	1,503
(b) Provisions	117	106
(c) Deferred tax liability, net	28	32
(d) Other non-current liabilities	1,160	1,025
<b>Non-current liabilities</b>	<b>6,049</b>	<b>5,805</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	1,770	1,397
Lease liabilities	18	8
Trade payables	1,592	1,514
Derivative liabilities	18	26
Other financial liabilities	358	382
(b) Provisions	131	109
(c) Income tax liability, net	193	152
(d) Other current liabilities	270	581
(e) Liabilities classified as held for sale	-	40
<b>Current liabilities</b>	<b>4,350</b>	<b>4,210</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>19,493</b>	<b>18,522</b>